Taiwan generics maker TWi adds ophthalmic asset

17 November 2017
mergers-acquisitions-big

Taipei-based generics maker TWi Pharmaceuticals (4180: TWO) has bought Synpac-Kingdom Pharmaceutical (SKP), another generics supplier known for ophthalmic treatments, for NT$1.8 billion ($59.8 million), reports The Pharma Letter’s China correspondent Wang Fangqing.

The deal is expected to be completed by the end of this year.

A major supplier to the US market, TWi sells complex generics including the dementia treatment donepezil hydrochloride tablets, a generic version of Eisai (TYO: 4523) and Pfizer’s (NYSE: PFE) Aricept, and the angina drug Nifedipine extended-release tablets, which was originally made by Bayer (BAYN: DE). In early November, it received approval of its Abbreviated New Drug (ANDA) application for the antidepressant bupropion Hcl ER, a generic version of GlaxoSmithKline’s (LSE: GSK) Wellbutrin (bupropion), from the US Food and Drug Administration.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Generics